Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms Abstract #1912

Introduction: Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to be asymptomatic and SREs are considered rare. The role of ART in preventing SREs in NEN has not been investigated so far.
Aim(s): To analyze the impact of ART on development of SREs in NEN patients.
Materials and methods: Retrospective analysis of our NEN database for all patients with BM who presented at our center between 08/2013 and 07/2015. Overall survival (OS) from diagnosis of BM as well as time to SRE (TTSRE) were calculated. In patients experiencing an SRE within 1 month after diagnosis (i.e. before efficacy of ART could be assessed), TTSRE was defined as the time to a subsequent SRE
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: Dr. med. Leonidas Apostolidis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#393 Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Differential Response of Bone Versus Soft Tissue Lesions
Introduction: Little is known about the treatment response of bone lesions to treatment with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Esther I. Van Vliet
#1271 Bone Metastases in NEN Patients - Frequency, Clinical, Therapeutic and Prognostic Relevance
Introduction: Up to 73% of patients with neuroendocrine neoplasms (NEN) present with distant metastases at diagnosis. Advanced stage negatively correlates with prognosis. Bone metastases (BM) are usually reported in less than 10% of patients. Improved imaging results in more frequent detection but information in general is very limited.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Michael Scharf
Authors: Scharf M, Michel V, Rinke A, Gress T, ...
#1898 Over Treatment Radionuclide Therapy (PRRT) of Metastatic Neuroendocrine Neoplasm (NEN) – A Case Report.
Introduction: Over treatment radionuclide therapy (PRRT) of metastatic neuroendocrine neoplasm (NEN).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Karolina Poczkaj
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience
Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Valeria Smiroldo
Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, ...